Emily Menendez

DocwireNews

New results from the randomized, phase 2/3 GABARNANCE trial were presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting by Masafumi Ikeda, MD.
<a href="https://meetings.asco.org/abstracts-presentations/231155" target="_blank" rel="noopener">GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy plus S-1</a> to determine which can be established as a standard neoadjuvant treatment for patients with borderline resectable pancreatic cancer (BRPC).
S-1 is a novel oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine used for the treatment of multiple forms of cancer, including gastric and pancreatic cancers.
Between June 2017 and December 2022, the open-label, multicenter trial assigned 112 patients to receive intravenous (IV) gemcitabine 1000 mg/m2 plus IV nab-paclitaxel 125 mg/m2 on days 1, 8, and 15 for 2 treatment cycles (group A, 56 patients), with concurrent chemoradiotherapy (50.4 Gy/28 fractions) plus S-1 80 mg/m2 on the irradiation days (group B, 56 patients).
After undergoing neoadjuvant therapy, patients underwent surgical resection, if it was determined to be possible, followed by postoperative treatment with S-1 therapy for 6 months. The primary end point of phase 3 was overall survival (OS). A total of 110 patients (65 events) was required to detect a 17% difference in the 2-year OS (hazard ratio [HR], 0.70) with a 2-sided alpha level of 10% and power of 70%.
The median OS in groups A and B was 23.1 and 31.5 months, respectively. While no statistically significant difference in OS rates was observed between the 2 arms (HR, 0.758; 95% CI, 0.472-1.219; P=.2518), a large late separation of the Kaplan-Meier curves was seen after 18 months.
The difference in 2-year OS between the groups was 14.6% (group A, 48.2%; group B, 62.8%), and the separation continued until the end of the observed survival curves. A similar late separation in progression-free survival (PFS) was also seen after around 12 months, but this difference was not statistically significant (median PFS in group A, 12.6 months; median PFS in group B, 11.1 months; HR, 0.805; 95% CI, 0.535-1.212; P=.2565).
The resection rate did not differ between the 2 groups (group A, 60.7%; group B, 57.1%). The tumor response rate was higher in group A (16.1%) than in group B (8.9%), but the pathological response rate was higher in group B (30.4%) than in group A (14.3%). Neutropenia and thrombocytopenia occurred more in group A, while treatment-related anorexia was observed more frequently in group B. Both treatments were well tolerated.
In both OS and PFS, there was a delayed survival advantage of concurrent chemoradiotherapy with S-1, without any additional toxicity. An updated analysis featuring longer-term efficacy and toxicity data is planned for the future to verify the advantage of neoadjuvant chemoradiotherapy.

CardioNerds

Kevin M. Alexander, MD

Acoramidis Therapy Yields Positive Results in Patients With ATTR-CM by Reducing Hospitalizations

Tumor Differentiation and Survival Outcomes in Gastric Cancer: The Role of Neoadjuvant Chemotherapy

Gastric Cancer

Rob Dillard

The Importance of Targeting Therapies for Patients With Interstitial Cystitis

Urology

Latest News

GABARNANCE OS, PFS Results: Gemcitabine, Nab-Paclitaxel With Concurrent Chemoradiotherapy for Pancreatic Cancer

Pancreatic Cancer

GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy with S-1, a novel oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine.

GABARNANCE OS and PFS Results: Gemcitabine, Nab-Paclitaxel and Concurrent Chemoradiotherapy for Panc

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe